Dark

LLY
Eli Lilly & Co.
stock NYSE

At Close

May 16, 2025 3:59:30 PM EDT

757.80USD+3.342%(+24.51)4,645,121

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 16, 2025 9:27:30 AM EDT

735.00USD+0.233%(+1.71)37,205

After-hours

May 16, 2025 4:50:30 PM EDT

757.75USD-0.007%(-0.05)52,636

OverviewOptionsHistoricalExchangesShortsNews

Jan 28, 2022

06:37PM EST Eli Lilly and Company plans to invest $1 billion in a Cabarrus County manufacturing campus that will generate nearly 600 new jobs with an average wage of over $70,000. RTTNews

12:35PM EST Lilly To Inject $1B In New Manufacturing Facility In North Carolina, US Benzinga

12:30PM EST Eli Lilly Plans To Invest 400M In Manufacturing Facility In Ireland: Report Benzinga

12:16PM EST Eli Lilly Announces $1B Investment In New Manufacturing Facility In North Carolina Benzinga

12:15PM EST Lilly announces $1 billion investment in new manufacturing facility in North PR Newswire

11:10AM EST Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema Benzinga

08:16AM EST Eli Lilly and Company (LLY) said, based on top-line efficacy results from two pivotal phase 3 trials (SLE-BRAVE-I and II), the company has decided to discontinue the phase 3 development program for OLUMIANT in lupus. The company is working with investigators to appropriately conclude the phase 3 SLE long-term extension trial, SLE-BRAVE-X. RTTNews

08:05AM EST Eli Lilly And Incyte Announce Decision To Discontinue Phase 3 Development Program For OLUMIANT In Lupus Benzinga

08:03AM EST Lilly Decides To Discontinue Phase 3 Development Program For OLUMIANT In Lupus RTTNews

08:01AM EST Updates on OLUMIANT(r) (baricitinib) Phase 3 lupus program and FDA review for PR Newswire

07:31AM EST CHMP Issues Positive Opinion To Expand Jardiance Indication Based On Unprecedented Benefit In Adult Heart Failure Patients With Preserved Ejection Fraction Benzinga

Jan 25, 2022

02:41PM EST What Are Whales Doing With Eli Lilly Benzinga

05:34AM EST A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Earnings, Fed Meeting Benzinga

Jan 24, 2022

10:28PM EST FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why Benzinga

02:17PM EST Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments? Benzinga

02:04PM EST If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today Benzinga

07:54AM EST Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $272 Benzinga

Jan 21, 2022

12:01PM EST Expert Ratings For Eli Lilly Benzinga

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022 Benzinga

06:11AM EST DZ Bank Upgrades Eli Lilly to Buy, Announces $291 Price Target Benzinga

05:17AM EST Looking At Eli Lilly's Recent Whale Trades Benzinga

05:11AM EST Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field Benzinga

Jan 20, 2022

10:02AM EST Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 PR Newswire

Jan 18, 2022

06:36AM EST Abbisko, Lilly Ink Licensing Pact For Cardiometabolic Diseases Benzinga

04:36AM EST Abbisko Therapeutics Announced Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules; Abbisko Therapeutics is Eligible to Receive up to $258M in Potential Payments Plus Royalites Benzinga

04:30AM EST Evotec and Lilly Entered into Drug Discovery Collaboration in Metabolic Diseases; Evotec to Receive Undisclosed Upfront Payment Plus Up to $1B in Milestone Payments and Royalties Benzinga

01:52AM EST Evotec Enters Research Partnership With Lilly - Quick Facts RTTNews

01:39AM EST Evotec, Lilly Enter Drug Discovery Collaboration In Metabolic Diseases RTTNews

Jan 14, 2022

12:22PM EST WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge Benzinga

Jan 13, 2022

12:55PM EST Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares Benzinga

Jan 12, 2022

11:42AM EST Check Out What Whales Are Doing With LLY Benzinga

Jan 10, 2022

06:07AM EST ALX Oncology Provides Corporate Update And Highlights Key Milestones In 2022 Benzinga

06:00AM EST ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2022. GlobeNewswire Inc

Jan 9, 2022

05:00PM EST AbCellera and Its Collaborators Released New Preclinical Data Confirming That the Investigational Antibody Bebtelovimab Maintains Both Full and Potent Neutralization Activity Against the Omicron Variant and All Other Known SARS-COV-2 Variants of Concern Benzinga

Jan 6, 2022

02:00PM EST Lilly to Participate in the J.P. Morgan Healthcare Conference PR Newswire

09:45AM EST Pharma major Eli Lilly and Company ( LLY) said Thursday that it bought exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and peripheral nervous system. The deal involves an initial payment of $50 million to Entos including an equity investment. RTTNews

08:24AM EST The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales Benzinga

07:37AM EST Pharma major Eli Lilly and Company (LLY), a pharmaceutical firm, and Entos Pharmaceuticals' said in a joint statement on Thursday that Lilly has acquired exclusive rights of Entos' Fusogenix nucleic acid delivery technology, for an initial payment of $50 million, which includes an equity investment by Lilly in Entos. RTTNews

06:50AM EST Lilly And Entos Pharmaceuticals Enter Into Research And Collaboration Agreement To Support The Development Of Innovative Therapies In Multiple Neurologic Indications Benzinga

06:48AM EST Lilly, Entos Enter Into Deal To Support Development Of Innovative Therapies In Multiple Neurologic Indications RTTNews

06:45AM EST to Support the Development of Innovative Therapies in Multiple Neurologic Indications PR Newswire

Jan 4, 2022

09:31AM EST Wells Fargo Maintains Equal-Weight on Eli Lilly, Raises Price Target to $280 Benzinga

Dec 24, 2021

05:07AM EST Innovent Biologics Inc. said that the National Medical Products Administration or NMPA of China has accepted the supplemental New Drug Application (sNDA) for sintilimab plus bevacizumab biosimilar injection and chemotherapy in patients with EGFR-mutated non-squamous non-small cell lung-cancer (nsqNSCLC) who progressed after EGFR-TKI therapy. RTTNews

Dec 22, 2021

03:46PM EST White House Covid-19 Response Coordinator Zients Says Anti-viral Treatments Will Be Provided to States, Localities at No Charge Benzinga

Dec 21, 2021

01:15AM EST Eli Lilly and Co. (LLY) said on Tuesday that in a phase III trial, its investigational monoclonal antibody Lebrikizumab considerably reduced the severity of moderate-to-severe atopic dermatitis, when combined with topical corticosteroids. RTTNews

12:08AM EST Lilly's Phase 3 Study Of Lebrikizumab With Topical Corticosteroids Meets Primary And Key Secondary Endpoints RTTNews

12:01AM EST when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study PR Newswire

Dec 20, 2021

07:10AM EST Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $325 Benzinga

07:09AM EST Berenberg Maintains Buy on Eli Lilly, Raises Price Target to $305 Benzinga

Dec 17, 2021

10:18AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021 Benzinga

09:37AM EST What 5 Analyst Ratings Have To Say About Eli Lilly Benzinga

07:40AM EST Goldman Sachs Initiates Coverage On Eli Lilly with Neutral Rating, Announces Price Target of $236 Benzinga

Dec 15, 2021

11:45AM EST 'Another thing I keep hearing here at the $LLY investor meeting: "bariatric-surgery-like weight loss." That's the pitch for new drugs like tirzepatide....' -STAT News Writer Tweet Benzinga

11:31AM EST FDA Approves AbbVie's JAK Inhibitor Application For Active Psoriatic Arthritis Benzinga

10:38AM EST Shares of American pharmaceutical company Eli Lilly and Company (LLY) are up 8 percent on Wednesday's trading as the company raised its revenue outlook for fiscal 2021. RTTNews

09:44AM EST Nektar Therapeutics (NKTR) said that proof-of-concept data presented by its partner Eli Lilly & Co. showed that, in patients with moderate to severe atopic dermatitis, NKTR-358 (LY3471851) given every two weeks over a 12-week period resulted in a dose-dependent reduction in EASI scores. RTTNews

08:03AM EST The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO Benzinga

07:15AM EST Eli Lilly Increases 2021 Adj. Earnings Guidance; Announces RTTNews

06:57AM EST Lilly Sees FY21 Adj. EPS $8.15-$8.20 vs $7.13 Est. Benzinga

06:54AM EST Lilly Updates 2021 Guidance; On Track To Meet Goal Of Launching 20 New Medicines Over 10-year RTTNews

06:45AM EST Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; PR Newswire

Dec 14, 2021

05:01PM EST Eli Lilly Says Mirikizumab Demonstrates Superiority Over Placebo In Phase 3 Maintenance Study In Ulcerative Colitis, Supporting Regulatory Submissions In 2022 Benzinga

05:00PM EST Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study PR Newswire

Dec 13, 2021

04:04PM EST Eli Lilly And Co. (LLY) Declares $ 0.98 Dividend for Q1 22, Record Date 2/15/2022 RTTNews

04:00PM EST Lilly Declares Quarterly Dividend Of $0.98/share, Payable March 10/ Record Feb. 15 RTTNews

03:36PM EST Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend PR Newswire

02:36PM EST Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher Benzinga

01:08PM EST Mid-Day Market Update: Nasdaq Drops Over 100 Points; Foghorn Therapeutics Shares Surge Benzinga

10:03AM EST Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals Benzinga

06:19AM EST Why Foghorn Therapeutics Is Rising In Pre-market? RTTNews

06:03AM EST Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets RTTNews

06:02AM EST Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control Platform; Foghorn To Receive $300M Upfront And An Equity Investment By Lilly Of $80M At $20/Share Benzinga

06:01AM EST Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets PR Newswire

06:00AM EST - Establishesco-developmentandco-commercializationagreementonFoghornsselectiveBRMprogram and an additional undisclosed program GlobeNewswire Inc

Dec 12, 2021

09:46AM EST Loxo Oncology Announced Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at ASH 2021; Said In 252 Efficacy-evaluable Patients, 171 Responded Including Two Complete Responses, 137 Partial Responses Benzinga

09:43AM EST Loxo Oncology Announced Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at ASH 2021 Benzinga

09:30AM EST Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical PR Newswire

Dec 10, 2021

09:22AM EST Eli Lilly Pens $1.5B Pact With Regor For Metabolic Disease Therapies Benzinga

07:50AM EST The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares Benzinga

06:39AM EST Eli Lilly and Co. (LLY) said that it has reached a multi-year research collaboration and licensing agreement with Regor Therapeutics Group to discover, develop and commercialize novel therapies for metabolic disorders. RTTNews

06:32AM EST Lilly, Regor Therapeutics Enter Multi-year Collaboration To Discover And Develop Novel Therapies For Metabolic Disorders RTTNews

06:31AM EST Eli Lilly Reports Collab With Regor Therapeutics To Discover, Develop Novel Therapies For Metabolic Disorders; Lilly To Pay Regor Upfront $50M, Includes Equity Investment, Eligible For Up To $1.5B In Potential Payouts Benzinga

06:30AM EST Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to PR Newswire

Dec 9, 2021

09:50PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 Benzinga

09:47PM EST Wells Fargo Initiates Coverage On Eli Lilly with Equal-Weight Rating, Announces Price Target of $270 Benzinga

10:30AM EST Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients PR Newswire

Dec 8, 2021

10:10AM EST Veeva Systems Says Eli Lilly Centralizes Platform Operations To Gain Agility And Deliver Value With Co Benzinga

Dec 6, 2021

08:03AM EST Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns Benzinga

Dec 5, 2021

09:16PM EST FDA Expands Authorization For Lilly's COVID-19 Antibody RTTNews

Dec 3, 2021

02:58PM EST Eli Lilly Shares Quiet Following News Co.'s Bamlanivimab, Etesevimab Authorized For Neutralizing Antibody Therapy For Emergency Use in COVID-19 Patients Under 12 Benzinga

02:52PM EST neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12 PR Newswire

12:18PM EST Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years Benzinga

07:40AM EST The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering Benzinga

Dec 1, 2021

10:02AM EST Eli Lilly Reports Will Host Meeting for Investment Community On Wednesday, Dec. 15, 2021 At 9 a.m. EST To 4 p.m., Will Give Initial FY22 Guidance Benzinga

10:01AM EST Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at PR Newswire

Nov 30, 2021

05:25PM EST Lilly Canada Concludes Successful Negotiations With The Pan-Canadian Pharmaceutical Aliance For Baqsimi Benzinga

04:48PM EST Watching COVID-19 Antibody Drug Stocks; Wall Street Journal Earlier Reports 'Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates' Benzinga

04:24PM EST Hearing Eli Lilly Named New Long From Cramer Benzinga

Nov 29, 2021

06:58AM EST Tetra Bio-Pharma Inc. (TBPMF, TBP.TO) announced positive initial clinical data from its ongoing Phase 2 clinical trials--REBORN1 and PLENITUDE-- of QIXLEEF for cancer pain. RTTNews

Nov 19, 2021

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

05:36AM EST BMO Capital Initiates Coverage On Eli Lilly with Outperform Rating, Announces Price Target of $311 Benzinga

Nov 18, 2021

08:04AM EST Eli Lilly Reports Enrollment Of Patients In Emgality Versus Nurtec Head-To-Head Migraine Treatment Study Benzinga

08:02AM EST Emgality(r) Versus Nurtec(r) ODT Head-to-Head Migraine Preventive Treatment PR Newswire

Nov 17, 2021

10:01AM EST Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference PR Newswire

Nov 11, 2021

01:32PM EST Eli Lilly And Co Says FDA Accepts Supplemental New Drug Application And Grants Priority Review For Jardiance For Adults With Heart Failure Independent Of Left Ventricular Ejection Fraction Benzinga

01:30PM EST Jardiance(r) for adults with heart failure independent of left ventricular ejection fraction PR Newswire

08:31AM EST Lilly announces winners of inaugural Leonard Award, a global program PR Newswire

Nov 10, 2021

12:37PM EST Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters Benzinga

Nov 9, 2021

02:00PM EST Lilly to Participate in Wolfe Research Virtual Healthcare Conference PR Newswire

08:33AM EST Lilly : OLUMIANT Long-Term Safety Profile Established Up To 9.3 Years In Analysis On Rheumatoid Arthritis RTTNews

08:31AM EST OLUMIANT(r) Long-Term Safety Profile Established Up to 9.3 Years in Integrated PR Newswire

Nov 5, 2021

03:49PM EDT UPDATE: Eli Lilly Says 'Data from five Phase III studies demonstrated that daprodustat improved or maintained haemoglobin within target levels' Benzinga

03:02PM EDT Eli Lilly Report Its Jardiance Showed Consistent Cardio-Renal Benefits In Adults With Heart Failure With Left Ventricular Ejection Fraction Over 40% Regardless of Chronic Kidney Disease Status Benzinga

03:00PM EDT failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status PR Newswire

Nov 4, 2021

09:01AM EDT Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American PR Newswire

Nov 2, 2021

04:53PM EDT Why Eli Lilly Shares Traded Higher Today Benzinga

11:25AM EDT Metacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients Benzinga

11:11AM EDT Eli Lilly Says European Medicines Agency Concludes Rolling Review Of Bamlanivimab, Etesevimab For COVID-19 Following Withdrawal By Co. Benzinga

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:47AM EDT Eli Lilly Reports Added Purchase By US Gov't. Of Bamlanivimab With Etesevimab For Administration Together For Treatment Of Mild To Moderate COVID-19; Co. To Supply 614K Doses No Later Than Jan. 31, 2022 For $1.29B Benzinga

08:23AM EDT Drug maker Eli Lilly And Co. (LLY) announced Tuesday an agreement to supply 614,000 doses of bamlanivimab with etesevimab to the U.S. government no later than January 31, 2022 for a total of $1.29 billion. RTTNews

06:54AM EDT Lilly To Supply 614K Addl Doses Of Bamlanivimab, Etesevimab To US For Treatment Or Post-exposure Prevention Of COVID-19 RTTNews

06:45AM EDT Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the PR Newswire

Nov 1, 2021

12:00PM EDT Lilly to Participate in Bernstein's Second Annual Operational Decisions PR Newswire

Oct 28, 2021

04:01PM EDT Eli Lilly & Co Say Additional Verzenio Phase 3 MonarchE Trial Data Published In Annals Of Oncology Benzinga

04:01PM EDT Additional Verzenio(r) (abemaciclib) Phase 3 monarchE Trial Data Published in PR Newswire

07:15AM EDT Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022 Benzinga

Oct 26, 2021

08:49AM EDT Eli Lilly Q3 Earnings Beat Estimates, Boosts FY21 Guidance On Higher COVID-19 Therapy Sales Benzinga

08:36AM EDT The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children Benzinga

07:27AM EDT Eli Lilly: Q3 Earnings Insights Benzinga

07:09AM EDT While reporting weak earnings and higher revenues in its third quarter, drug maker Eli Lilly And Co. (LLY) on Tuesday trimmed its fiscal 2021 earnings view on a reported basis, while raised adjusted earnings and revenue forecast above market estimates. RTTNews

06:29AM EDT Eli Lilly And Co. (LLY) announced earnings for third quarter that dropped from the same period last year. RTTNews

06:28AM EDT Eli Lilly Sees FY21 Adj. EPS $7.95-$8.05 vs $6.80 Est. Benzinga

06:27AM EDT Eli Lilly Announced Initiation of a Rolling Submission for Donanemab to FDA for Accelerated Approval in Early Alzheimer's Disease Benzinga

06:27AM EDT Eli Lilly Q3 Adj. EPS $1.94 Beats $1.68 Estimate, Sales $6.77B Beat $5.70B Estimate Benzinga

06:26AM EDT Lilly Q3 Reported EPS $1.22; Non-GAAP EPS $1.94 RTTNews

06:25AM EDT Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success PR Newswire

06:03AM EDT A Peek Into The Markets: US Stock Futures Rise Ahead Of Big Earnings Benzinga

04:39AM EDT Earnings Scheduled For October 26, 2021 Benzinga

Oct 25, 2021

11:15AM EDT Earnings Preview For Eli Lilly Benzinga

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 22, 2021

04:26PM EDT A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO Benzinga

09:53AM EDT Price Over Earnings Overview: Eli Lilly Benzinga

Oct 19, 2021

07:01AM EDT Adults with type 2 diabetes with increased cardiovascular risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine, as per Eli Lilly and Co's (LLY) SURPASS-4 clinical trial results. The trial results were published in The Lancet. RTTNews

06:48AM EDT Lilly : Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes With Increased CV Risk RTTNews

06:47AM EDT Eli Lilly Highlights Tirzepatide Results Published In The Lancet Benzinga

06:45AM EDT reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk PR Newswire

Oct 18, 2021

04:01PM EDT Eli Lilly And Co. (LLY) Declares $ 0.85 Dividend for Q4 21, Record Date 11/15/2021 RTTNews

02:52PM EDT Lilly Declares Fourth-Quarter 2021 Dividend PR Newswire

Oct 16, 2021

04:15PM EDT Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More Benzinga

Oct 14, 2021

01:34PM EDT Eli Lilly & Co Updates Verzenio Phase 3 MonarchE Trial Data Presented At ESMO Virtual Plenary And Simultaneously Published In Annals Of Oncology Benzinga

01:30PM EDT Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology PR Newswire

Oct 13, 2021

01:38PM EDT The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal Benzinga

07:01AM EDT Eli Lilly and Company (LLY) said the FDA has approved its Verzenio, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of at or above 20%. RTTNews

06:49AM EDT Lilly: FDA Approves Verzenio As First And Only CDK4/6 Inhibitor For People With HR+ HER2- High Risk Early Breast Cancer RTTNews

06:45AM EDT FDA Approves Verzenio(r) (abemaciclib) as the First and Only CDK4/6 Inhibitor PR Newswire

06:41AM EDT Eli Lilly Received FDA Approval Tuesday for Verzenio for Efficacy Under NDA 208716 Benzinga

Oct 12, 2021

10:02AM EDT Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial PR Newswire

09:31AM EDT Moderna Inc. (MRNA) said that Gavi, the Vaccine Alliance has exercised its option to purchase an additional 176.5 million doses of the Moderna COVID-19 vaccine for the COVAX Facility. RTTNews

Oct 11, 2021

01:33PM EDT AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial Benzinga

01:03PM EDT Where Eli Lilly Stands With Analysts Benzinga

10:51AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021 Benzinga

07:35AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:56AM EDT Berenberg Upgrades Eli Lilly to Buy, Raises Price Target to $270 Benzinga

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Oct 7, 2021

09:56AM EDT Price To Earnings Ratio Insights For Eli Lilly Benzinga

09:10AM EDT Eli Lilly's Loxo Oncology Announces Details Of Presentation At 2021 AACR-NCI-EORTC Conference Benzinga

09:05AM EDT Loxo Oncology At Lilly Announces Details Of Presentations On Molecular Targets And Cancer Therapeutics RTTNews

09:01AM EDT AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics PR Newswire

07:36AM EDT Sonoco (SON) said that it is implementing a $60 per ton price increase for all grades of uncoated recycled paperboard in the United States and Canada, effective with shipments beginning November 1, 2021. RTTNews

Oct 5, 2021

09:08AM EDT Bringing Mental Health Pharmacology into the 21st Century: How the Marriage of Enveric Biosciences and MagicMed Industries Could Revolutionize the Way We Treat Mental Health Benzinga

Oct 4, 2021

01:29PM EDT UPDATE: Recent Batch Of Glucagon Emergency Kits Was Manufactured At Indiana Factory Cited By Regulators For Quality-Control Violations Benzinga

01:28PM EDT Eli Lilly & Co's Recalled Emergency Diabetes Drug Came From Plant Cited By FDA Benzinga

09:01AM EDT First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals PR Newswire

Oct 1, 2021

03:02PM EDT Eli Lilly's Debt Overview Benzinga

11:19AM EDT Eli Lilly's Mirikizumab Maintains Symptomatic Remission for Two Years In Ulcerative Colitis Patients Benzinga

09:01AM EDT At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab PR Newswire

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

07:23AM EDT Eli Lilly Shares Positive Tirzepatide Data At EASD Annual Meeting Benzinga

06:40AM EDT Eli Lilly and Co. (LLY) and Incyte (INCY) announced Thursday detailed results from two pivotal Phase 3 trials of OLUMIANT (baricitinib) in treating Alopecia Areata or AA. RTTNews

06:03AM EDT Lilly Announces Detailed Results From Two Pivotal Phase 3 Trials Of BRAVE-AA1 And BRAVE-AA2 For Alopecia Areata RTTNews

05:59AM EDT Eli Lilly and Company And Incyte Announce OLUMIANT Significantly Improved Hair Regrowth To At Least 80% Scalp Coverage As Early As 24 Weeks Across First Completed Phase 3 Studies For Alopecia Areata Benzinga

05:56AM EDT OLUMIANT(r) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage PR Newswire

05:38AM EDT Eli Lilly and Co. (LLY) Thursday announced positive results from two SURPASS-3 sub-studies of Tirzepatide in adults with Type 2 Diabetes. Both continuous glucose monitoring or CGM sub-study and magnetic resonance imaging or MRI sub-study of phase 3 SURPASS-3 clinical trial achieved their primary and secondary endpoints. RTTNews

04:55AM EDT Lilly Says SURPASS-3 MRI Sub-study Of Tirzepatide Meets Primary And Secondary Endpoints In Adults With Type 2 Diabetes RTTNews

04:40AM EDT Lilly's tirzepatide led to greater improvements in liver fat content compared PR Newswire

04:37AM EDT Lilly Says SURPASS-3 CGM Sub-study Meets Primary And Secondary Endpoints In Adults With Type 2 Diabetes RTTNews

04:30AM EDT Lilly's tirzepatide led to greater time in range compared to insulin degludec PR Newswire

Sep 29, 2021

03:09PM EDT Why Eli Lilly Shares Are Moving Higher Today Benzinga

01:18PM EDT What 8 Analyst Ratings Have To Say About Eli Lilly Benzinga

10:12AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2021 Benzinga

10:03AM EDT Lilly, Susan G. Komen Partner To Address Disparities In Breast Cancer Outcomes Experienced By Black Women RTTNews

10:01AM EDT Lilly and Susan G. Komen(r) Partner to Address Disparities in Breast Cancer PR Newswire

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

07:36AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:09AM EDT Citigroup Upgrades Eli Lilly to Buy, Raises Price Target to $265 Benzinga

Sep 28, 2021

10:27PM EDT Eli Lilly and Co. (LLY) said that the U.S. Food and Drug Administration has granted approval of a new indication for Erbitux or cetuximab injection in combination with Braftovi or encorafenib, marketed by Pfizer, Inc., for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. RTTNews

05:50PM EDT Eli Lilly Says FDA Expands Co's ERBITUX (cetuximab) Label With Combination Of BRAFTOVI (encorafenib) For Treatment Of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) After Prior Therapy Benzinga

05:45PM EDT BRAFTOVI(r) (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy PR Newswire

06:59AM EDT Eli Lilly and Co. (LLY) Tuesday said it will lower the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective January 1, 2022. The move will effectively bring the list price down to 2008 levels, the company said. RTTNews

06:41AM EDT Eli Lilly Lowers Price Of Insulin Lispro Injection By Additional 40% Effective Jan. 1 Benzinga

06:34AM EDT Lilly To Lower List Price Of Insulin Lispro Injection In The U.S. By An Additional 40%, Effective Jan 1 RTTNews

06:31AM EDT Lilly again reduces list price of Insulin Lispro Injection as latest change to PR Newswire

Sep 27, 2021

08:06AM EDT Eli Lilly Says New Data From Verzenio MonarchE Study To Be Featured In ESMO Virtual Plenary Benzinga

08:01AM EDT New Data from Verzenio(r) (abemaciclib) monarchE Study to Be Featured in ESMO PR Newswire

05:57AM EDT Eli Lilly Recalls Batch Of Low Blood Sugar Med Due To Health Risk Benzinga

02:08AM EDT Eli Lilly and Co. is recalling one lot of GLUCAGON Emergency Kit for low blood sugar to the consumer/user level citing loss of potency, the U.S. Food and Drug Administration announced. RTTNews

Sep 24, 2021

08:12PM EDT Eli Lilly and Company?Issues Voluntary?Nationwide Recall of?One Lot of PR Newswire

Sep 21, 2021

04:15PM EDT Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities PR Newswire

01:57PM EDT Lilly To Supply EU, EEA With Up To 220,000 Doses Of AbCellera-Discovered Bamlanivimab Together With Etesevimab For Treatment Of Confirmed COVID-19 Benzinga

01:39PM EDT Lilly Confirms Earlier Report Co Won Procurement Agreement With European Commission To Supply Bamlanivimab And Estesevimab Together For Treatment Of Confirmed COVID-19 Benzinga

01:38PM EDT bamlanivimab and etesevimab together for the treatment of confirmed COVID-19 PR Newswire

12:19PM EDT European Commission Signs Contract With Eli Lilly For Supply Of A Monoclonal Antibody Treatment Benzinga

07:01AM EDT Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059 PR Newswire

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 16, 2021

05:26PM EDT Eli Lilly and Company (LLY) Thursday said that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization for bamlanivimab and etesevimab administered together to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection. RTTNews

04:16PM EDT AbCellera Biologics Reports FDA Emergency Use Authorization for Its Bamlanivimab, Etesevimab Administered Together Expanded To Include Post-Exposure Prophylaxis For COVID-19; Same News As Eli Lilly Earlier Benzinga

03:58PM EDT Eli Lilly Reports FDA Emergency Use Authorization for Its Bamlanivimab, Etesevimab Administered Together Expanded To Include Post-Exposure Prophylaxis For COVID-19 Benzinga

03:57PM EDT administered together expanded to include post-exposure prophylaxis for COVID-19 PR Newswire

Sep 15, 2021

08:01AM EDT After Regeneron, US Government Orders Additional COVID-19 Therapy From Eli Lilly Benzinga

07:57AM EDT After Regeneron, US Govt. Orders For Additional COVID-19 Therapy From Eli Lilly Benzinga

07:54AM EDT U.S. Govt Calls For Additional Doses Of Regeneron's COVID-19 Antibody Therapy Benzinga

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

07:05AM EDT Eli Lilly and Co.(LLY) said that it will supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 Additional doses of etesevimab will be paired with existing bamlanivimab purchased by the U.S. government. RTTNews

06:48AM EDT Lilly To Supply Additional 388K Doses Of Etesevimab To U.S. Government For COVID-19 RTTNews

06:47AM EDT Lilly To Supply 388,000 Doses Of Etesevimab To U.S. Government For Treatment Of Covid-19; Co. Reports This Transaction Is Expected To Generate ~$330M In Revenue Benzinga

06:45AM EDT Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of PR Newswire

Sep 13, 2021

10:01AM EDT Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference PR Newswire

08:07AM EDT Lilly To Present New Data From Oncology Portfolio At ESMO Congress; To Be Held Virtually September 16-21 RTTNews

08:01AM EDT Lilly to Present New Data from Oncology Portfolio at ESMO Congress PR Newswire

Sep 10, 2021

07:36PM EDT Eli Lilly Reports In 13G Filing A 5.6% Stake In ProQR Therapeutics Benzinga

Sep 9, 2021

02:00PM EDT Lilly Prices First Sustainability Bond to Advance Global ESG Strategy PR Newswire

08:47AM EDT Eli Lilly and Company (LLY) announced FDA has granted Breakthrough Therapy designation for Jardiance as an investigational treatment for adults with heart failure with preserved ejection fraction. The decision is based on results from the EMPEROR-Preserved phase III trial. RTTNews

08:17AM EDT The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization Benzinga

08:04AM EDT Lilly : FDA Grants Jardiance Breakthrough Therapy Designation For Heart Failure With Preserved Ejection Fraction RTTNews

08:02AM EDT FDA Grants Jardiance Breakthrough Therapy Designation For heart Failure With Preserved Ejection Fraction Benzinga

08:01AM EDT FDA grants Jardiance(r) Breakthrough Therapy designation for heart failure with PR Newswire

Sep 8, 2021

04:04PM EDT ProQR Announces Axiomer RNA Editing Licensing And Research Collaboration With Lilly Benzinga

Sep 7, 2021

09:12AM EDT Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to PR Newswire

06:16AM EDT Eli Lilly and Company (LLY) has commenced a cash tender offer for up to $1.5 billion combined aggregate principal amount of specified series of its outstanding debt securities. The early tender date is September 20, 2021, unless extended. The tender offer is scheduled to expire on October 4, 2021. RTTNews

06:02AM EDT Lilly Begins Cash Tender Offer For Up To $1.5 Bln Combined Aggregate Principal Amount Of Debt Securities RTTNews

06:00AM EDT Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate PR Newswire

Sep 3, 2021

12:50PM EDT Wall Street Crime And Punishment: Martha Stewart's Perfectly Ridiculous Stock Scandal Benzinga

10:01AM EDT Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare PR Newswire

Sep 2, 2021

08:35AM EDT FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know Benzinga

Aug 31, 2021

02:00PM EDT Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference PR Newswire

Aug 30, 2021

03:55PM EDT Can COVID-19 Antibody Treatment Help In High-Risk Cases? Mayo Clinic, nference Study Shows Potential Benzinga

01:31PM EDT Eli Lilly Says Empagliflozin Data Shows Statistically Significant Improvement In Heart Failure Outcomes In Adults With Preserved Ejection Fraction Benzinga

01:30PM EDT New empagliflozin data shows statistically significant improvement in heart PR Newswire

01:06PM EDT Where Eli Lilly Stands With Analysts Benzinga

document.getElementById("XbmdKp").onerror = function(){this.style.display='none';}; .dark-mode .PHtr88{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .PHtr88{ color: #333333; background-color: white; border: 2px solid #333333; }LLYEli Lilly & Co.stock NYSE

LLY
Eli Lilly & Co.
stock NYSE